|COMAC – China’s future “national pride” and response to Boeing and Airbus|
|Author: Matej Balen|
|18th July 2018|
|SHANGHAI - The Commercial Aircraft Corporation of China, COMAC, has announced on July 16th that it has signed a letter of intent with HNA Group for an order of 20 ARJ21 regional passenger planes. This brings the total number of ARJ21 orders to 473 globally.|
The Commercial Aircraft Corporation of China, Ltd. (Comac) is a Chinese state-owned aerospace manufacturer established in May 2008 in Shanghai, with a registered capital of UDS 2.7 billion. Company was established to design and construct large passenger aircrafts with capacities of over 150 passengers, in an effort aimed to reduce China's dependency on Boeing and Airbus.
The first jet designed by COMAC was marketed under the name Comac ARJ21 with the capacity up to 105 passengers for regional flights, whose deliveries started in 2015. With this week’s signing with HNA Group, total orders came to 473 globally, including from the USA, Indonesia, and some African and Southeast-Asian countries, outside China.
Comac C919 is the second jet developed by the company, with the passenger capacity up to 168. It had it first flight in May 2017, and as of July 2018 has received 1,015 orders from the biggest Chinese airlines, and from the USA and Thailand. HNA Group has recently made the biggest order of C919 - 200 planes.
Two wide-body airplanes currently being developed by COMAC are C929 (passenger capacity 290) and C939 (capacity 400) which will have their first flights in the next 5-10 years.
In China, COMAC bears the weight to be China’s future “national pride”, with the goals set to take 20% of the world’s market share amongst manufacturers by 2035, currently dominated by Boeing and Airbus. To meet these goals, in March 2011, COMAC signed a framework agreement for a long-term strategic cooperation with Canadian company Bombardier, and in May 2017 with Russia's United Aircraft Corporation (UAC).
|31st March 2021|
|WHO: Sinopharm, Sinovac COVID-19 vaccine data show efficacy|